FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreThe U.S. Departments of the Treasury, Labor, and Health and Human Services issued a new proposed rule Oct. 27, that outlines policies related to the No Surprises Act (NSA) independent dispute resolution (IDR) process. The rule addresses disclosure of claim eligibility information by insurers, communication during the open negotiation period, collection of administrative fees and batching multiple claims into a single IDR dispute.
On initial review of the proposed rule, the departments appear to address the concerns raised by the American College of Radiology® (ACR®) with regard to lack of communication about claim eligibility, IDR backlogs and access to the IDR process for low-cost claims, including batching requirements. The government proposes to expand batching to allow multiple codes from a single patient encounter. In addition, the departments propose to allow batching by groupings of Current Procedural Terminology® (CPT®) codes, rather than single CPT codes. These are positive changes, but ACR remains concerned about other proposals, including limiting batching to 25 line items in a single dispute.
ACR continues to review the details of this proposed rule and will provide a detailed summary. For more information or if you have questions, contact Katie Keysor, ACR Senior Director of Economic Policy.
FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreLower Fee Now in Effect to File No Surprises Act Disputes
Federal agencies released a final rule that updates the No Surprises Act independent dispute resolution process. The rule lowers the IDR administrative or filing fee from $115 to $15.
Read moreACR Urges Funding for NIH All of Us Program
ACR urges Congress to provide dedicated funding for NIH’s All of Us Research Program, a leader in precision medicine technologies and a valuable tool for researchers.
Read more